FibroGen, Inc.

NasdaqGS:FGEN Stock Report

Market Cap: US$65.6m

FibroGen Management

Management criteria checks 2/4

FibroGen's CEO is Thane Wettig, appointed in Jul 2023, has a tenure of 1.5 years. total yearly compensation is $3.64M, comprised of 15.7% salary and 84.3% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $146.95K. The average tenure of the management team and the board of directors is 13.4 years and 6.1 years respectively.

Key information

Thane Wettig

Chief executive officer

US$3.6m

Total compensation

CEO salary percentage15.7%
CEO tenure1.5yrs
CEO ownership0.2%
Management average tenure13.4yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

Dec 25
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19
The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 06

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

May 28

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

May 07
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22
FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24
A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18
Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12
The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06
Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31
Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05
Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08
Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

CEO Compensation Analysis

How has Thane Wettig's remuneration changed compared to FibroGen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$122m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$4mUS$573k

-US$284m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$322m

Mar 31 2023n/an/a

-US$307m

Dec 31 2022US$3mUS$535k

-US$294m

Sep 30 2022n/an/a

-US$362m

Jun 30 2022n/an/a

-US$220m

Mar 31 2022n/an/a

-US$281m

Dec 31 2021US$3mUS$510k

-US$290m

Sep 30 2021n/an/a

-US$215m

Jun 30 2021n/an/a

-US$231m

Mar 31 2021n/an/a

-US$183m

Dec 31 2020US$4mUS$263k

-US$189m

Compensation vs Market: Thane's total compensation ($USD3.64M) is above average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Thane's compensation has increased whilst the company is unprofitable.

CEO

Thane Wettig (59 yo)

1.5yrs

Tenure

US$3,640,829

Compensation

Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...

Leadership Team

NamePositionTenureCompensationOwnership
Thane Wettig
CEO & Director1.5yrsUS$3.64m0.22%
$ 146.9k
Christine Chung
Senior Vice President of China Operations18yrsUS$3.11m0.30%
$ 196.3k
Barry Berkowitz
Founder30yrsno datano data
David DeLucia
Chief Financial Officerless than a yearno data0.12%
$ 77.1k
Michael Lowenstein
Chief Legal Officer8.8yrsno datano data
Julian Stern
Secretary32yrsUS$27.13kno data

13.4yrs

Average Tenure

59yo

Average Age

Experienced Management: FGEN's management team is seasoned and experienced (13.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thane Wettig
CEO & Director1.3yrsUS$3.64m0.22%
$ 146.9k
George Martin
Chairman of Scientific Advisory Boardno datano datano data
Jeffrey Edwards
Independent Director9.3yrsUS$385.53k0.025%
$ 16.7k
James Schoeneck
Independent Chairman of the Board14.8yrsUS$499.58k0.081%
$ 53.1k
Maykin Ho
Independent Director6.1yrsUS$375.53k0.023%
$ 15.1k
Aoife Brennan
Independent Director4.4yrsUS$373.03k0.020%
$ 12.8k

6.1yrs

Average Tenure

63yo

Average Age

Experienced Board: FGEN's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 10:25
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

FibroGen, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Kennen MacKayCredit Suisse
Matthew KellerH.C. Wainwright & Co.